Bruce Rapley
Bruce Rapley has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
- Matt Shelton
Independent Researcher, New Zealand
3 shared publications
Latest Publications
- Open Access
- 31 January 2026
- Published by MDPI AG in Preprints.org
Proteomic Characterisation of Anomalous Intravascular Casts Reveals Non-Canonical Fibrin Architecture and Impaired Fibrinolysis
Since early 2021, anomalous intravascular casts (AICs) have been reported that differ markedly from conventional thrombi in morphology, persistence, and mechanical behavior. Prior histological and elemental analyses suggested an atypical clot matrix.We performed blinded proteomic profiling of AIC specimens using HPLC-MS/MS (High Precision Liquid Chromatography - tandem Mass Spectrometry) to characterize their protein composition and assess markers of fibrin architecture and fibrinolytic capacity.Proteomic analysis identified 541 human proteins, dominated by fibrin-family components. However, fibrinogen chains were present in highly abnormal proportions, with pronounced depletion of the α chain relative to β and γ chains. Plasminogen was detected at extremely low abundance (0.1283% of total protein), indicating a severe deficiency in intrinsic fibrinolytic machinery.AICs exhibit a reproducible proteomic phenotype incompatible with typical fibrin biology, characterized by chain imbalance and fibrinolysis resistance. These findings support classification of AICs as structurally and functionally abnormal clot entities and motivate further mechanistic investigation.
- 31 January 2026
- Published by MDPI AG in Preprints.org
Open AccessProteomic Characterisation of Anomalous Intravascular Casts Reveals Non-Canonical Fibrin Architecture and Impaired Fibrinolysis
Since early 2021, anomalous intravascular casts (AICs) have been reported that differ markedly from conventional thrombi in morphology, persistence, and mechanical behavior. Prior histological and elemental analyses suggested an atypical clot matrix.We performed blinded proteomic profiling of AIC specimens using HPLC-MS/MS (High Precision Liquid Chromatography - tandem Mass Spectrometry) to characterize their protein composition and assess markers of fibrin architecture and fibrinolytic capacity.Proteomic analysis identified 541 human proteins, dominated by fibrin-family components. However, fibrinogen chains were present in highly abnormal proportions, with pronounced depletion of the α chain relative to β and γ chains. Plasminogen was detected at extremely low abundance (0.1283% of total protein), indicating a severe deficiency in intrinsic fibrinolytic machinery.AICs exhibit a reproducible proteomic phenotype incompatible with typical fibrin biology, characterized by chain imbalance and fibrinolysis resistance. These findings support classification of AICs as structurally and functionally abnormal clot entities and motivate further mechanistic investigation.
- Open Access
- 28 January 2026
- Published by MDPI AG in Preprints.org
Elemental Characterisation of Anomalous Intravascular Casts Reveals an Abnormal Biochemical Matrix
In the first paper of this trilogy, anomalous intravascular casts (AICs) were established as a discrete morphological–histological phenotype distinct from conventional antemortem thrombi and ordinary postmortem clots. While those findings demonstrated that AICs form coherent, lumen-conforming intravascular structures under conditions of active blood flow, morphology and histology alone cannot determine the biochemical nature of the matrix from which such structures are formed.Blinded, multi-site elemental analyses were performed on anomalous intravascular casts using inductively coupled plasma mass spectrometry (ICP-MS). Elemental compositions were benchmarked against whole-blood reference values and first-principles stoichiometric expectations derived from fibrinogen to assess compatibility with canonical fibrin-based clot biochemistry.AICs exhibited reproducible, non-physiological elemental ratios characterized by marked sulfur depletion, relative phosphorus enrichment, and imbalance within bulk elemental relationships. These compositional features are incompatible with protein-dominant fibrin matrices and could not be explained by simple fibrin overload, cellular aggregation, or classical coagulation artifacts.The elemental composition of anomalous intravascular casts is inconsistent with canonical thrombus biochemistry and supports the presence of a non-canonical intravascular matrix. These findings independently corroborate the structural conclusions of the first paper in this series and establish the need for protein-level analysis to identify the molecular constituents underlying this anomalous material, which is addressed in the final paper of this trilogy.
- 28 January 2026
- Published by MDPI AG in Preprints.org
Open AccessElemental Characterisation of Anomalous Intravascular Casts Reveals an Abnormal Biochemical Matrix
In the first paper of this trilogy, anomalous intravascular casts (AICs) were established as a discrete morphological–histological phenotype distinct from conventional antemortem thrombi and ordinary postmortem clots. While those findings demonstrated that AICs form coherent, lumen-conforming intravascular structures under conditions of active blood flow, morphology and histology alone cannot determine the biochemical nature of the matrix from which such structures are formed.Blinded, multi-site elemental analyses were performed on anomalous intravascular casts using inductively coupled plasma mass spectrometry (ICP-MS). Elemental compositions were benchmarked against whole-blood reference values and first-principles stoichiometric expectations derived from fibrinogen to assess compatibility with canonical fibrin-based clot biochemistry.AICs exhibited reproducible, non-physiological elemental ratios characterized by marked sulfur depletion, relative phosphorus enrichment, and imbalance within bulk elemental relationships. These compositional features are incompatible with protein-dominant fibrin matrices and could not be explained by simple fibrin overload, cellular aggregation, or classical coagulation artifacts.The elemental composition of anomalous intravascular casts is inconsistent with canonical thrombus biochemistry and supports the presence of a non-canonical intravascular matrix. These findings independently corroborate the structural conclusions of the first paper in this series and establish the need for protein-level analysis to identify the molecular constituents underlying this anomalous material, which is addressed in the final paper of this trilogy.
- Open Access
- 26 January 2026
- Published by MDPI AG in Preprints.org
Morphological and Histological Characterisation of Anomalous Intravascular Casts (AICs)
Anomalous intravascular casts with firm, rubber-elastic properties have been increasingly noted by embalmers and clinicians since 2021. To establish their structural characteristics, we performed blinded morphological and histological evaluations. Gross examination revealed elongated, lumen-filling casts up to 25 cm in length, frequently branching and demonstrating elastic resistance atypical of conventional thrombi. Histology demonstrated dense fibrinous lamination with intermittent Lines of Zahn and various cellular inclusions content, suggesting antemortem formation under atypical hemodynamic conditions. These structural features differ from both physiological thrombi and postmortem clots, indicating a distinct pathological phenotype. Further biochemical and molecular analyses will be required to determine the composition and mechanisms underlying these structures.
- 26 January 2026
- Published by MDPI AG in Preprints.org
Open AccessMorphological and Histological Characterisation of Anomalous Intravascular Casts (AICs)
Anomalous intravascular casts with firm, rubber-elastic properties have been increasingly noted by embalmers and clinicians since 2021. To establish their structural characteristics, we performed blinded morphological and histological evaluations. Gross examination revealed elongated, lumen-filling casts up to 25 cm in length, frequently branching and demonstrating elastic resistance atypical of conventional thrombi. Histology demonstrated dense fibrinous lamination with intermittent Lines of Zahn and various cellular inclusions content, suggesting antemortem formation under atypical hemodynamic conditions. These structural features differ from both physiological thrombi and postmortem clots, indicating a distinct pathological phenotype. Further biochemical and molecular analyses will be required to determine the composition and mechanisms underlying these structures.
- Open Access
- 4 January 2025
- Published by Institute for Vaccine Theory, Practice, and Research in International Journal of Vaccine Theory, Practice, and Research
- Vol. 4 (1) , 1487-1516
From Innovation to Inquiry — COVID-19 mRNA Vaccination and Its Global Consequences — with Special Reference to New Zealand
The COVID-19 pandemic involved the rapid deployment of novel biomedical technologies. Chief among them were synthetic RNAs, introduced with limited longitudinal data, yet supported by institutional consensus, and expedited regulatory pathways. Subsequent developments revealed questions regarding safety, ethics, efficacy, and governance. This formal review, with specific reference to New Zealand, examines the COVID-19 response, using synthetic RNA distributed under Emergency Use Authorizations. A range of post-deployment signals, including immunological anomalies (IgG4 class switching), clotting disorders, and residual DNA elements, remain insufficiently investigated. Regulatory responses have not met the standard of precaution typically applied to novel gene therapies. At the same time, low-cost interventions such as ivermectin were de-prioritized, or suppressed. The temporal association between vaccine rollouts and excess non-COVID mortality in several high-uptake nations warrants systematic, transparent analysis. To date, no national authority has published comprehensive disaggregated mortality data by vaccination status.
- 4 January 2025
- Published by Institute for Vaccine Theory, Practice, and Research in International Journal of Vaccine Theory, Practice, and Research
- Vol. 4 (1) , 1487-1516
Open AccessFrom Innovation to Inquiry — COVID-19 mRNA Vaccination and Its Global Consequences — with Special Reference to New Zealand
The COVID-19 pandemic involved the rapid deployment of novel biomedical technologies. Chief among them were synthetic RNAs, introduced with limited longitudinal data, yet supported by institutional consensus, and expedited regulatory pathways. Subsequent developments revealed questions regarding safety, ethics, efficacy, and governance. This formal review, with specific reference to New Zealand, examines the COVID-19 response, using synthetic RNA distributed under Emergency Use Authorizations. A range of post-deployment signals, including immunological anomalies (IgG4 class switching), clotting disorders, and residual DNA elements, remain insufficiently investigated. Regulatory responses have not met the standard of precaution typically applied to novel gene therapies. At the same time, low-cost interventions such as ivermectin were de-prioritized, or suppressed. The temporal association between vaccine rollouts and excess non-COVID mortality in several high-uptake nations warrants systematic, transparent analysis. To date, no national authority has published comprehensive disaggregated mortality data by vaccination status.